Surrogate MR markers of response to chemo- or radiotherapy in association with co-treatments: A retrospective analysis of multi-modal studies

Contrast Media and Molecular Imaging

Volumn 5, Issue 6, 2010, Pages 323-332

  Jordan, Bénédicte F ^a   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

EPR; Imaging endpoint; MRI; Multi modal; Surrogate marker; Theranostics; Tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; BOTULINUM TOXIN; CARBOGEN; CYCLOPHOSPHAMIDE; HYDROCORTISONE; INSULIN; ISOSORBIDE DINITRATE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NEUTRAL INSULIN; SEMAXANIB; THALIDOMIDE; VANDETANIB; XANTHINOL NICOTINATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; ELECTRON SPIN RESONANCE; EXPERIMENTAL NEOPLASM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEMODYNAMICS; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIMETRY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR BLOOD FLOW; TUMOR MICROENVIRONMENT; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; ENDPOINT DETERMINATION; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; OXIMETRY; OXYGEN; PROGNOSIS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 78650671148     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.397     Document Type: Article

References (56)

1. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J. Magn. Reson. Imag 2002; 16: 430-450.
2. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82: 699-757.
3. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276.
4. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007; 25: 4066-4074.
5. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, Swartz HM. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000; 2: 152-165.
6. Gallez B, Baudelet C, Jordan BF. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed 2004; 17: 240-262.
7. Sonveaux P. Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol 2008; 86: 300-313.
8. Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 1995; 34: 313-316.
9. Biaglow JE, Manevich Y, Leeper D, Chance B, Dewhirst MW, Jenkins WT, Tuttle SW, Wroblewski K, Glickson JD, Stevens C, Evans SM. MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. Int J Radiat Oncol Biol Phys 1998; 42: 871-876.
10. Jordan BF, Grégoire V, Demeure RJ, Sonveaux P, Feron O, O'Hara J, Vanhulle VP, Delzenne N, Gallez B. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 2002; 62: 3555-3561.
11. Crokart N, Radermacher K, Jordan BF, Baudelet C, Cron GO, Grégoire V, Beghein N, Bouzin C, Feron O, Gallez B. Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res 2005; 65: 7911-7916.
12. Crokart N, Jordan BF, Baudelet C, Cron GO, Hotton J, Radermacher K, Grégoire V, Beghein N, Martinive P, Bouzin C, Feron O, Gallez B. Glucocorticoids modulate tumor radiation response through a decrease in tumor oxygen consumption. Clin Cancer Res 2007; 13: 630-635.
13. Ansiaux R, Baudelet C, Jordan BF, Crokart N, Martinive P, DeWever J, Grégoire V, Feron O, Gallez B. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res 2006; 66: 9698-9704.
14. Ansiaux R, Dewever J, Gregoire V, Feron O, Jordan BF, Gallez B. Decrease in tumor cell oxygen consumption after treatment by vandetanib (ZD6474) and its effects on response to radiotherapy. Radiat. Res 2009; 172: 584-591.
15. Jordan BF, Christian N, Crokart N, Grégoire V, Feron O, Gallez B. Thyroid status is a key modulator of tumor oxygenation: implication for radiation therapy. Radiat Res 2007; 168: 428-432.
16. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000; 48: 565-570.
17. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imag 1999; 10: 223-232.
18. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imag 2005; 30: 324-341.
19. Jordan BF, Gallon JP, Gillies RJ. Post-treatment changes in tumor microenvironment: dynamic contrast enhanced and diffusion weighted magnetic resonance imaging. Cancer Imag, 2008; 2: 235-248.
20. Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M, Lederle W, Woenne EC, Hengerer A, Taupitz M, Semmler W, Kiessling F. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imag 2009; 29: 1125-1133.
21. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001; 14: 497-506.
22. Baudelet C, Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn Reson Med 2002; 48(6): 980-986.
23. Robinson SP, Rijken PF, Howe FA, McSheehy PM, van der Sanden BP, Heerschap A, Stubbs M, van der Kogel AJ, Griffiths JR. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imag 2003; 17: 445-454.
24. Swartz HM, Clarkson RB. The measurement of oxygen in vivo using EPR techniques. Phys Med Biol 1998; 43: 1957-1975.
25. Krishna MC, Devasahayam N, Cook JA, Subramanian S, Kuppusamy P, Mitchell JB. Electron paramagnetic resonance for small animal imaging applications. ILAR J 2001; 42: 209-218.
26. Vikram DS, Zweier JL, Kuppusamy P. Methods for noninvasive imaging of tissue hypoxia. Antioxid Redox Signal 2007; 9: 1745-1756.
27. Pogue BW, O'Hara JA, Demidenko E, Wilmot CM, Goodwin IA, Chen B, Swartz HM, Hasan T. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res 2003; 63: 1025-1033.
28. Hou H, Khan N, Grinberg OY, Yu H, Grinberg SA, Lu S, Demidenko E, Steffen RP, Swartz HM. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res 2007; 168: 218-225.
29. Elas M, Bell R, Hleihel D, Barth ED, McFaul C, Haney CR, Bielanska J, Pustelny K, Ahn KH, Pelizzari CA, Kocherginsky M, Halpern HJ. Electron paramagnetic resonance oxygen image hypoxic fraction plus radiation dose strongly correlates with tumor cure in FSa fibrosarcomas. Int J Radiat Oncol Biol Phys 2008; 71: 542-549.
30. Diepart C, Jordan BF, Gallez B. A New EPR oximetry protocol to estimate the tissue oxygen consumption in vivo. Radiat Res 2009; 172: 220-225.
31. Amorino GP, Lee H, Holburn GE, Paschal CB, Hercules SK, Shyr Y, Steffen RP, Choy H. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13. Radiat Res 2001; 156: 294-300.
32. * is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imag 2004; 19: 482-488.
33. Kiessling F, Huber PE, Grobholz R, Heilmann M, Meding J, Lichy MP, Fink C, Krix M, Peschke P, Schlemmer HP. Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy. Invest Radiol 2004; 39: 34-44.
34. Viglianti BL, Lora-Michiels M, Poulson JM, Lan L, Yu D, Sanders L, Craciunescu O, Vujaskovic Z, Thrall DE, Macfall J, Charles CH, Wong T, Dewhirst MW. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin. Cancer Res 2009; 15: 4993-5001.
35. Yamashita Y, Baba T, Baba Y, Nishimura R, Ikeda S, Takahashi M, Ohtake H, Okamura H. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 2000; 216: 803-809.
36. George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA, Swift RI. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001; 88: 1628-1636.
37. Loncaster JA, Carrington BM, Sykes JR, Jones AP, Todd SM, Cooper R, Buckley DL, Davidson SE, Logue JP, Hunter RD, West CM. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys 2002; 54: 759-767.
38. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003; 89: 1889-1895.
39. Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicolato E, Giusti A, Pesenti E, Terron A, Sbarbati A, Abrams T, Murray L, Osculati F. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 2004; 10: 739-750.
40. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005; 7: 475-485.
41. Nagashima T, Sakakibara M, Nakamura R, Arai M, Kadowaki M, Kazama T, Nakatani Y, Koda K, Miyazaki M. Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients. Eur J Radiol 2006; 60: 270-274.
42. Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, d'Arcy JA, Collins DJ, Pittam MR, Ravichandran D, Padhani AR. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14: 6580-6589.
43. van Laarhoven HW, Klomp DW, Rijpkema M, Kamm YL, Wagener DJ, Barentsz JO, Punt CJ, Heerschap A. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 2007; 20: 128-140.
44. Mason RP, Hunjan S, Constantinescu A, Song Y, Zhao D, Hahn EW, Antich PP, Peschke P. Tumor oximetry: comparison of 19F MR EPI and electrodes. Adv Exp Med Biol 2003; 530: 19-27.
45. Clarkson RB, Odintsov BM, Ceroke PJ, Ardenkjaer-Larsen JH, Fruianu M, Belford RL. Electron paramagnetic resonance and dynamic nuclear polarization of char suspensions: surface science and oximetry. Phys Med Biol 1998; 43: 1907-1920.
46. Jennings D, Raghunand N, Gillies RJ. Imaging hemodynamics. Cancer Metastasis Rev 2008; 27: 589-613.
47. Cron GO, Beghein N, Ansiaux R, Martinive P, Feron O, Gallez B. 19F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy. Magn Reson Med 2008; 59: 19-27.
48. Schlemmer HP, Becker M, Bachert P, Dietz A, Rudat V, Vanselow B, Wollensack P, Zuna I, Knopp MV, Weidauer H, Wannenmacher M, van Kaick G. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res 1999; 59: 2363-2369.
49. Taper HS, Woolley GW, Teller MN, Lardis MP. A new transplantable mouse liver tumor of spontaneous origin. Cancer Res 1966; 26: 143-148.
50. Volpe JP, Hunter N, Basic I, Milas L. Metastatic properties of murine sarcomas and carcinomas I. positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clin. Expl. Metastasis 1985; 3: 281-294.
51. James PE, Jackson SK, Grinberg OY, Swartz HM. The effects of endotoxin on oxygen consumption of various cell types in vitro: an EPR oximetry study. Free Radic Biol Med 1995; 18: 641-647.
52. Fan X, Medved M, River JN, Zamora M, Corot C, Robert P, Bourrinet P, Lipton M, Culp RM, Karczmar GS. New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med 2004; 51: 487-494.
53. *-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys Med Biol 2004; 49: 3389-3411.
54. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, Martinive P, Grégoire V, Feron O, Gallez B. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005; 11: 743-750.
55. Segers J, Crokart N, Danhier P, Grégoire V, Jordan BF, Gallez B. Use of xanthinol nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors. Int J Cancer 2010; 126(2): 583-588.
56. Ansiaux R, Baudelet C, Cron GO, Segers J, Dessy C, Martinive P, De Wever J, Verrax J, Wauthier V, Beghein N, Grégoire V, Buc Calderon P, Feron O, Gallez B. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res 2006; 12: 1276-1283.